Ranbaxy, GSK in JV for initiate phase I trial

Ranbaxy Laboratories has initiated phase I clinical trial of a lead compound for respiratory inflammation, a company release said today.

This is part of a joint collaborative programme with GlaxoSmithKline.

The company added that the trials will be conducted in India and Europe.

The release further added that Ranbaxy will receive a milestone payment for initiating the phase I studies and will also be responsible for conducting phase II clinical studies.